Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 7/20 | 0.36 |
| ▸ | CA12 | O43570 | 5/20 | 0.36 |
| ▸ | CA1 | P00915 | 5/20 | 0.36 |
| ▸ | CA2 | P00918 | 5/20 | 0.36 |
| ▸ | CA9 | Q16790 | 5/20 | 0.36 |
| ▸ | MMP8 | P22894 | 4/20 | 0.35 |
| ▸ | MMP1 | P03956 | 3/20 | 0.35 |
| ▸ | ANPEP | P15144 | 2/20 | 0.33 |
| ▸ | ERAP2 | Q6P179 | 2/20 | 0.33 |
| ▸ | METAP2 | P50579 | 2/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.31 |
| ▸ | MMP3 | P08254 | 2/20 | 0.31 |
| ▸ | MMP9 | P14780 | 1/20 | 0.31 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.31 |
| ▸ | ACE | P12821 | 1/20 | 0.31 |
| ▸ | METAP1 | P53582 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4266943 | 1.00 | MMP2 (0.36) | MMP2CA12CA1CA2CA9 | |
| SCHEMBL4265150 | 1.00 | MMP2 (0.36) | MMP2CA12CA1CA2CA9 | |
| SCHEMBL7027254 | 0.88 | MMP2 (0.37) | MMP2CA12CA1CA2CA9 | |
| SCHEMBL27574167 | 0.86 | MMP2 (0.35) | MMP2CA12CA1CA2CA9 | |
| SCHEMBL12477720 | 0.85 | MMP2 (0.36) | MMP2CA12CA1CA2CA9 | |
| SCHEMBL28646794 | 0.85 | MMP2 (0.36) | MMP2CA12CA1CA2CA9 | |
| SCHEMBL12477242 | 0.84 | CA12 (0.33) | MMP2CA12CA1CA2CA9 | |
| SCHEMBL12477609 | 0.81 | ACE (0.34) | MMP2CA12CA1CA2CA9 | |
| Phosphoric Acid SCHEMBL28317933 | 0.77 | MMP2 (0.38) | MMP2CA12CA1CA2CA9 | |
| SCHEMBL4269654 | 0.76 | KDM4E (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090069268-A1 | NOVEL PHOSPHORAMIDATE COMPOUNDS AND METHODS OF USE | CELMED ONCOLOGY (USA), INC. | 2009-03-12 | — | — | US | disclosed |
| US-7462605-B2 | Phosphoramidate compounds and methods of use | CELMED ONCOLOGY (USA), INC. (CA) | 2008-12-09 | — | — | US | disclosed |
| US-20030109697-A1 | Novel phosphoramidate compounds and methods of use | KIADIS PHARMA INTELLECTUAL PROPERTY B.V. (NL) | 2003-06-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069268-A1 | NOVEL PHOSPHORAMIDATE COMPOUNDS AND METHODS OF USE | MTAP, TYMP, INPP5D | MMP2 4569/4885CA12 2604/4885CA1 2676/4885 |
| US-20030109697-A1 | Novel phosphoramidate compounds and methods of use | MTAP, INPP5D, TYMP | MMP2 4681/4885CA12 2682/4885CA1 2801/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.